Johnson & Johnson (JNJ) said Sunday that results from a phase 2 trial of its experimental combination of Talvey and Tecvayli showed a nearly 79% overall response rate with durability in patients with a certain type of cancer.
The results cover patients with triple-class exposed relapsed or refractory multiple myeloma who have true extramedullary disease.
The company said that 54% of the patients achieved a complete response or better in the study. Results from responders indicated "deep and durable" responses, the company said.
Treatment with the combination led to 61% of patients progression free and alive at one year, Johnson & Johnson said.
Extramedullary disease represents an aggressive form of multiple myeloma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.